

## Post immunization COVID-19 disease: Correspondence

Dear Editor,

We would like to share ideas on the publication “Post immunization COVID-19 disease.”<sup>[1]</sup> Bawaskar and Bawaskar described cases of COVID-19 sickness in people who had received the COVID-19 vaccine. Regardless of immunization status, victims with symptoms should be evaluated for the likelihood of severe acute respiratory syndrome COVID-beta 2 (SARS-CoV-2) viral infection, according to Bawaskar and Bawaskar. The requirement for a COVID-19 booster dosage was verified by these findings. We agree that COVID-19 illness can occur after vaccination. This is always a problem in any situation, with a major concern in the area of using a low-effective vaccine as a background vaccine. When discussing the post-immunization COVID-19 and the effect of conventional vaccination/boostering, the influence of the background vaccination regimen should be considered. The third dosage of vaccine is confirmed to be effective, and its effectiveness is determined by the background immunization and the type of booster vaccine used.<sup>[2]</sup>

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

**Beuy Joob<sup>1</sup>, Viroj Wiwanitkit<sup>2</sup>**

<sup>1</sup>Sanitation1 Medical Academic Center, Bangkok, Thailand,  
<sup>2</sup>Department of Community Medicine, Honorary Professor,  
Dr. D. Y.Patil University, Pune, Maharashtra, India

**Address for correspondence:** Dr. Beuy Joob,  
Sanitation1 Medical Academic Center, Bangkok, Thailand.  
E-mail: beuyjoob@hotmail.com

### References

1. Bawaskar HS, Bawaskar PH. Post immunization COVID-19 disease. *J Family Med Prim Care* 2022;11:1555-7.
2. Yasri S, Wiwanitkit V. Expected response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background. *Int J Physiol Pathophysiol Pharmacol* 2022;14:1-3.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**Received:** 06-05-2022

**Revised:** 16-05-2022

**Accepted:** 10-07-2022

**Published:** 31-10-2022

### Access this article online

#### Quick Response Code:



**Website:**  
www.jfmpc.com

**DOI:**  
10.4103/jfmpc.jfmpc\_1012\_22

**How to cite this article:** Joob B, Wiwanitkit V. Post immunization COVID-19 disease: Correspondence. *J Family Med Prim Care* 2022;11:6612.

© 2022 Journal of Family Medicine and Primary Care | Published by Wolters Kluwer - Medknow